3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
2
Congenital Abnormalities
2
Wilms Tumor
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Recurrence
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Neutropenia
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Neutrophilic, Chronic
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Chronic-Phase
1
Interventions
Rituximab
168
Cyclophosphamide
142
Peripheral Blood Stem Cell Transplantation
84
fludarabine phosphate
68
Filgrastim
64
Etoposide
63
Radiotherapy
55
Vincristine
47
Prednisone
45
Mycophenolic Acid
44
Melphalan
40
Whole-Body Irradiation
39
Cyclosporine
39
Busulfan
39
Tacrolimus
36
Doxorubicin
34
Cytarabine
33
Lenalidomide
29
Carmustine
28
Antilymphocyte Serum
28
Methotrexate
27
Methylprednisolone
26
Bortezomib
26
Bendamustine Hydrochloride
26
sargramostim
21
ibritumomab tiuxetan
20
obinutuzumab
19
ibrutinib
18
fludarabine
18
Dexamethasone
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, Follicular
×
Lithium Carbonate
×
Clear all
NCT00408681
2017-03-07
GVHD
Fred Hutchinson Cancer Center
Phase NA
Completed
20 enrolled
27 charts